In the simulator, insulin-pramlintide algorithms improved time in range by 3.00% to 10.53% versus their insulin-alone counterparts.
In plain wordsIn computer simulations, insulin-pramlintide algorithms improved time in range compared with corresponding insulin-alone algorithms.
- Peptide
- Pramlintide (Symlin)
- Outcome
- IncreaseTime in range
- Study
n: not reported in source
T1DM UVA/Padova simulator- Comparator
- Corresponding insulin-alone algorithms
- Outcome group
- Glycemic control · Metabolic and weight
Measurements
- Time in range improvement
- 3 to 10.53%
- Insulin-pramlintide versus insulin alone
Source sentences
The results of the insulin-pramlintide algorithms are compared against their insulin-alone counterparts, showing an improvement in the time in range between 3.00% and 10.53%, consistent with results reported in clinical trials in the literature.
1 context sentence(design, population, supporting numbers)
This work incorporates a recent pramlintide pharmacokinetics/pharmacodynamics model into the T1DM UVA/Padova simulator to adjust and validate four insulin-plus-pramlintide control algorithms.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).